IDEMIA
10.12.2020 17:47:11 CET | Business Wire | Press release
IDEMIA, the global leader in Augmented Identity, and Kudelski IoT, a division of the Kudelski Group (SIX: KUD.S), the world leader in digital security and IoT solutions, today announced a joint solution for mobile network operators (MNOs), mobile virtual network operators (MVNOs), original equipment manufacturers (OEMs) and service providers to enable efficient IoT device provisioning at scale, without compromising on connectivity or data security.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201210005726/en/
With the growth of IoT deployments globally, the security of devices and client data stored or collected within the device has become one of the biggest concerns across the ecosystem and its users. IDEMIA, member of the Trusted Connectivity Alliance (TCA1 ), and Kudelski IoT are taking on the challenge of data privacy and device protection with a simplified, end-to-end security solution for IoT deployments designed to securely connect devices to the cloud. This solution is particularly relevant since OEMs and service providers are looking for solutions using embedded Secure Elements to protect content.
IDEMIA’s IoT SAFE solution provides the added benefit of remote management and provisioning of over-the-air (OTA) security certificates and application updates directly to the highly secure SIM environment. This also provides the ability to keep the solution up-to-date with evolving security standards.
By seamlessly integrating the Kudelski IoT Root of Trust applet and keySTREAM system within IDEMIA’s secure elements and OTA platform, OEMs, MNOs and service providers now have a solution to leverage for their own security services for their customers and end users.
The combination of IDEMIA and Kudelski’s leading positions within their respective areas of excellence ensures a simplified approach to enabling security for IoT devices and platforms, allowing plug & play installation for connected security use cases.
“The industry has been expecting standards to be defined for IoT Security. Together with GSMA and the TCA, those standards and guidelines are now in place with IoT SAFE. Thanks to our partnership with Kudelski, IDEMIA is proud to bring this technology breakthrough solution to the market. The market can now benefit from an independent technology with the added benefit of ensuring end-to-end device and data security for IoT,” said Fabien Jautard Executive Vice-President for Mobile Operators activities at IDEMIA.
“By combining IDEMIA’s Mobile Network SIMs and OTA platform with Kudelski IoT keySTREAM into a solution specifically tailored for cellular machine-to-machine communications, we bring to the market the first truly standard and dedicated end-to-end IoT security solution for mobile networks,” said Hardy Schmidbauer, SVP, Kudelski IoT.
1 TCA is a global, non-profit industry association which is working to enable a secure connected future. Its members are participants within the SIM ecosystem, which is the most widely distributed, secure application delivery platform in the world.
About IDEMIA’s Mobile Operators Business unit
IDEMIA serves clients in 180 countries and is trusted by over 500 mobile operators globally. With over 850 million SIM cards, 100 + eSIM platform references and over 2.2 eSIM consumer transactions in 2019, IDEMIA is leading the way in eSIM and remote subscription management for consumer and M2M spaces and end-to-end biometric solutions. Making MNOs the next identity providers. IDEMIA benefits from its global manufacturing footprint (Brazil, France, India and China) and cutting-edge security data centers in Europe and the United States. Our solutions are trusted by the largest Groups worldwide. Our Continuous innovation is fueled by strong R&D investments and close partnerships in IoT/M2M - Connectivity - Biometrics – Security – Encryption – QoS/QoE – Advanced SIM & services areas.
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter
About Kudelski IOT
Kudelski IoT is the Internet of Things division of The Kudelski Group and provides end-to-end IoT solutions, IoT product design, and full-lifecycle services to IoT device manufacturers, ecosystem creators and end-user companies. These solutions and services leverage the group’s 30+ years of innovation in digital business model creation; hardware, software and ecosystem design and testing; state-of-the-art security lifecycle management technologies and services and managed operation of complex systems. For more information about Kudelski IOT, please visit www.kudelski-iot.com .
About Kudelski Group
The Kudelski Group (SIX: KUD.S) is a world leader in digital security and a provider of end-to-end convergent media solutions to the digital entertainment industry, including services and applications requiring access control and rights management to secure the revenue in digital television, internet, mobile and interactive applications. The Group also offers cybersecurity solutions and services focused on helping companies assess risks and vulnerabilities and protect their data and systems. It also supplies integrated solutions to manage access control of people and vehicles to sites and events. The Kudelski Group is headquartered in Cheseaux-sur-Lausanne, Switzerland and Phoenix (AZ), USA. For more information, please visit www.nagra.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005726/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
